is the fda banning compounded tirzepatide New project announcement: HHS‑OIG taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Ban on Compounded GLP-1

Regularly inspect vials for seal integrity

FDA approves new drug treatment for chronic weight management, first since 2014, Food and Drug Administration (2021) Wegovy efficacy & safety profile, Novo Nordisk Semaglutide injection, National Library of Medicine MedlinePlus (2023) Common side effects of Wegovy, Novo Nordisk Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

doi:10.1152/ajpendo.00298.2015 Hooi JKY, Lai WY, Ng WK, et al

By diligently managing utilization, WellDyne delivered significant cost savings through: Undisputed Results Despite the denial of over 50% of requests for access to GLP-1s, only 10% were appealed by the prescriberreinforcing that most knew they were prescribing the medications more aggressively than necessary

doi:10.1167/iovs.10-5264 13